Drug Profile
Research programme: oncology therapeutics - Medac Pharma
Alternative Names: MPI-2710; MPI-2720; MPI-2730; MPI-3501Latest Information Update: 21 Dec 2018
Price :
$50
*
At a glance
- Originator Medac; Medac Pharma
- Class
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological malignancies
Most Recent Events
- 13 Dec 2018 Pediapharm is now called Medexus Pharmaceuticals
- 16 Oct 2018 Medac Pharma has been acquired by Pediapharm
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in USA